$ICCC SEC Filings

Filed On	Filing
13 Oct 2026	8-K: Results of Operations and Financial Condition ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
13 Aug 2026	FORM 10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
09 Jul 2026	8-K: Results of Operations and Financial Condition
22 Jun 2026	Form 4: te Boekhorst Paul Francis Olivier, Director Bought 8,000 shares ($76K)
17 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
10 Jun 2026	8-K: Regulation FD Disclosure
14 May 2026	FORM 10-Q
14 May 2026	8-K: Results of Operations and Financial Condition
13 May 2026	FORM 10-K/A
08 May 2026	8-K: Entry into a Material Definitive Agreement
24 Apr 2026	Proxy statement: annual meeting on June 11, 2026 CEO pay $676K · say-on-pay vote
23 Apr 2026	Form 3: DiMarco Anthony, Director
23 Apr 2026	Form 3: Guillemette Gilles, Director
16 Apr 2026	Form 4: Turner Kathy V, Director Granted 17,899 Non Qualified Stock Options (Right to buy)
16 Apr 2026	Form 4: Tomsche David Scott, Director Granted 11,933 Non Qualified Stock Options (Right to buy)
16 Apr 2026	Form 4: Basse Gloria F, Director Granted 11,933 Non Qualified Stock Options (Right to buy)
16 Apr 2026	Form 4: Wainman Paul R, Director Granted 11,933 Non Qualified Stock Options (Right to buy)
14 Apr 2026	Form 4: Gathagan Bryan K., Director Granted 10,000 Non Qualified Stock Options (Right to buy)
14 Apr 2026	Form 4: Wainman Paul R, Director Granted 10,000 Non Qualified Stock Options (Right to buy)

Comments